Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 17, 2017

M&As this week: Court Square Capital Partners, Quotient Sciences Limited, Jinzi Ham

Court Square Capital Partners has acquired a majority stake in clinical research organisation Celerion Holdings from MTS Health Investors.

Court Square Capital Partners has acquired a majority stake in clinical research organisation Celerion Holdings from MTS Health Investors.

Both Court Square and MTS Health are private equity firms.

All the entities involved in the acquisition are based in the US.

Quotient Sciences has acquired contract development and manufacturing organisation Pharmaterials.

This acquisition enables the drug development services organisation to expand its services in the UK.

Both Quotient Sciences and Pharmaterials are based in the US.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
“PhoenixBio plans to acquire Canadian in-vivo research services provider KMT Hepatech for C$5.5m ($4.33m).”

Jinzi Ham plans to acquire a 37.14% stake in NovaBay Pharmaceuticals for $27.06m.

Jinzi Ham is a Chinese food production company, whereas NovaBay Pharmaceuticals is a US-based biopharmaceutical company.

PhoenixBio plans to acquire Canadian in-vivo research services provider KMT Hepatech for C$5.5m ($4.33m).

KMT Hepatech will become a subsidiary of the Japanese life-science company upon completion of the acquisition.

Arlington Capital Partners has acquired a majority stake in contract, development, and manufacturing organisation Grand River Aseptic Manufacturing (GRAM).

Both the companies involved are based in the US.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU